In-vitro studies with four new antifungal agents: BAY n 7133, bifonazole (BAY h 4502), ICI 153,066 and Ro 14-4767/002.
Four new antifungal agents were compared in vitro with miconazole and ketoconazole. The agents were BAY n 7133 and ICI 153,066, two orally active triazoles, and bifonazole (BAY h 4502) and Ro 14-4767/002, both topical agents. While all four were found to be broad spectrum antifungal agents they also demonstrated certain gaps in their spectra. In general, Ro 14-4767/002 was the most active agent tested whereas bifonazole and BAY n 7133 were the least active. Noteworthy activities included that of Ro 14-4767/002 against Candida albicans, the dermatophytes and Sporothrix schenckii and that of ICI 153,066 against Torulopsis glabrata.
D000935:Antifungal Agents / Q000494:pharmacology*; D003883:Arthrodermataceae / Q000187:drug effects; D001758:Blastomyces / Q000187:drug effects; D002175:Candida / Q000187:drug effects; D003045:Coccidioides / Q000187:drug effects; D003455:Cryptococcus neoformans / Q000187:drug effects; D004353:Drug Evaluation, Preclinical; D006658:Histoplasma / Q000187:drug effects; D007093:Imidazoles / Q000494:pharmacology*; D007654:Ketoconazole / Q000494:pharmacology; D008825:Miconazole / Q000494:pharmacology; D009025:Morpholines / Q000494:pharmacology*; D013175:Sporothrix / Q000187:drug effects; D014230:Triazoles / Q000494:pharmacology*
D000935:Antifungal Agents; D007093:Imidazoles; D009025:Morpholines; D014230:Triazoles; C040032:ICI 153066; D008825:Miconazole; C037494:vibunazole; C038974:amorolfine; C036596:bifonazole; D007654:Ketoconazole